BioTime (NYSEMKT: BTX), a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies.
BTX’s product candidates include Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV related facial lipoatrophy; OpRegen, which is in Phase I/IIa clinical trial for the treatment of the dry form of age-related macular degeneration; HyStem-BDNF, a preclinical development program for the delivery of recombinant human brain-derived neurotrophic factor (BDNF) directly into the stroke cavity of patients for aiding in tissue repair and functional recovery; and ReGlyde that is in preclinical development as a device for viscosupplementation and a combination product for drug delivery in osteoarthritis.
BTX also develops AST-OPC1, a therapy derived from pluripotent stem cells that is in a Phase I/IIa clinical trial for spinal cord injuries; AST-VAC1, a patient-specific cancer immunotherapy that is in Phase II clinical trial for acute myeloid leukemia; and AST-VAC2, a non-patient specific cancer immunotherapy, which is in Phase I/IIa clinical trial to treat non-small cell lung cancer. In addition, it offers liquid biopsy tests for diagnosis of cancer; bone grafting products to treat orthopedic disorders; and mobile health software products.
Further, it markets GeneCards, a human gene database; LifeMap Discovery, a database of embryonic development, stem cell research, and regenerative medicine; MalaCards, a human disease database; VarElect, an application for prioritizing gene variants; and GeneAnalytics, a novel gene set analysis tool. Additionally, the company develops and markets Hextend, a blood plasma volume expander used for the treatment of hypovolemia.
BioTime, Inc. was founded in 1990 and is based in Alameda, California.
October 28, 2016
RegMed Investors’ (RMi) closing bell analysis, Opexa’s (OPXA) MS trial failure suppresses any uptick
October 27, 2016
RegMed Investors’ (RMi) closing bell analysis, sector goes down in the count
October 27, 2016
Lower open expected; RegMed Investors’ (RMi) pre-open, let’s buck the downside trend
October 26, 2016
RegMed Investors’ (RMi) closing bell analysis, development promises and promises …
October 26, 2016
Sharply lower open expected; RegMed Investors’ (RMi) pre-open, exposure …
October 25, 2016
RegMed Investors’ (RMi) closing bell analysis, sector struggles with buoyancy as quarterly reporting season begins
October 25, 2016
Higher open expected; RegMed Investors’ (RMi) pre-open, make sure the brake pedals work, the sector can’t get out of its own way
October 19, 2016
RegMed Investors’ (RMi) closing bell analysis, risk tolerance defines the sector
October 19, 2016
Flat to lower open expected; RegMed Investors’ (RMi) pre-open, feed me more upside begs the sector!
October 13, 2016
RegMed Investors’ (RMi) closing bell analysis, sector suffers lethargy – a lack of enthusiasm
35 companies, 1 interpreter!
Insight, foresight and recommendation
BioTime, Inc. (BTX) -- open 1/1/18 at $2.29, rolled to $3.05 by 2/1 but, has been slipping to $2.60 on 2/16. Needs news and differentiation of the story and the definition of their multiple markets addressed ... also rolls with news yet a complacent stock ...
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.